Table II.
Bivariate Cox proportional hazards models for overall survival
| Bivariate Models | Hazard Ratio | 95% CI | P-value |
|---|---|---|---|
| Pre-treatment pEBVd+ | 2.04 | 0.96–4.36 | 0.06 |
| Age ≥60 | 2.22 | 1.01–4.88 | 0.05 |
| Pre-treatment pEBVd+ | 1.71 | 0.80–3.69 | 0.17 |
| Stage IV | 3.20 | 1.28–7.99 | 0.01 |
| Pre-treatment pEBVd+ | 2.18 | 0.94–5.05 | 0.07 |
| ECOG PS >1 | 2.85 | 1.28–6.37 | 0.01 |
| Pre-treatment pEBVd+ | 2.11 | 0.97–4.61 | 0.06 |
| Elevated LDH | 2.18 | 0.92–5.16 | 0.08 |
| Pre-treatment pEBVd+ | 1.34 | 0.59–3.05 | 0.48 |
| >1 Extranodal Site | 3.11 | 1.37–7.05 | 0.007 |
| Pre-treatment pEBVd+ | 1.55 | 0.64–3.73 | 0.33 |
| BM Involvement | 2.44 | 1.11–5.36 | 0.03 |
| Pre-treatment pEBVd+ | 1.47 | 0.61–3.57 | 0.39 |
| IPI 3–5 | 2.68 | 0.98–7.37 | 0.06 |
| Pre-treatment pEBVd+ | 2.17 | 1.01–4.67 | 0.05 |
| ALCL ALK+ | 0.98 | 0.23–4.24 | 0.98 |
| Pre-treatment pEBVd+ | 2.91 | 1.33–6.40 | 0.008 |
| AITL | 0.38 | 0.15–0.97 | 0.04 |
pEBVd=plasma EBV-DNA; PS=performance status; LDH=lactate dehydrogenase; BM=bone marrow; IPI=International Prognostic Index, 1 point for age>60yo, PS>1, LDH elevated, >1 extranodal site, stage III/IV; ALCL=anaplastic large cell lymphoma, ALK=anaplastic lymphoma kinase;